Search results
Showing 1 to 8 of 8 results for dulaglutide
Awaiting development [GID-TA10439] Expected publication date: TBC
Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)
This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18. The guideline recommends how to support children and young people and their families and carers to maintain tight control of blood glucose to reduce the long-term risks associated with diabetes.
Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.
This evidence summary has been updated and replaced by NICE guideline NG28.
In development [GID-TA11104] Expected publication date: TBC
New treatment option recommended for people with type 2 diabetes
Around 180,000 people with difficult to manage type 2 diabetes could benefit from tirzepatide as new treatment option for type 2 diabetes.
More evidence needed to recommend Type 2 diabetes treatment tirzepatide
More evidence is needed on the clinical and cost-effectiveness of a new treatment option for people with type 2 diabetes before it could be recommended for NHS use